AEterna Zentaris

Committed to cure by discovering and developing innovative drugs for the treatment of patients suffering from some forms of cancer, endocrinian disorders and infectious diseases, this is our mission. Therefore, our dedicated and motivated staff is committed to the pursuit of our excellence program based on performance, quality and integrity towards patients and the healthcare community, as well as to our shareholders to secure them with an optimum return in light of their trust towards our work. Products on the market Æterna Zentaris Inc., the "Company" formed following the acquisition of German-based company Zentaris by Æterna Laboratories Inc., benefits from significant added credibility in regard to the development of targeted therapies. The research and development teams have proven their abilities as experts at gearing the development of compounds to precise strategic targets. This track record has succeeded in attracting lucrative partnership and financing agreements at all stages of the development process. Since its beginning, the Company has engaged in the discovery and development of novel drugs culminating with the launch of two products for serious or life-threatening diseases. Products in development In the biopharmaceutical business, risk is best managed through the pursuit and availability of different clinical and preclinical projects. Æterna Zentaris’ pipeline follows a multi-track endeavour in three principal therapeutic fields: oncology, endocrinology and anti-infectives. Besides its proprietary drug discovery unit, the Company’s global scientific network produces a steady stream of innovative new development projects to create breakthrough medicines for patients in need. Growth strategy The Æterna Zentaris business model is to discover and develop innovative products mostly through alliances with pharmaceutical and biotech companies. In case of licensing, the Company reaps revenues from projects even at the earliest stage of development. This latter model minimizes risk through alliance commitments that provide for Æterna Zentaris’ partners to pay most development costs, while Æterna Zentaris retains significant commercial rights.

Contact Details: 1405 du Parc-Technologique Blvd Québec G1P 4P5 Canada Tel: (418) 652-8525 Fax: (418) 652-0881 Email: WWW: www.aeternazentaris.com

Loading...

Recent Publications by AEterna Zentaris:
Development of AEZS-115 (ZEN-019) by optimization of structurally unique, orally active, peptidomimetic GnRH antagonists. Fibroblasts from scaffold-based three-dimensional human cultures have been...	6th June, 2009	AEterna Zentaris GmbH, Discovery and Preclinical Development,	Adv Exp Med Biol. 2009;611:521-2.

Press Releases on AEterna Zentaris:
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology	11th November, 2009	AETERNA ZENTARIS INC.	Updated Analyses of Phase 1/2 Clinical Trial of Perifosine in Combination with Bortezomib (+/- Dexamethasone) to be Presented on Saturday, December 5, 2009 QUEBEC CITY, Nov. 11
AEterna Zentaris Reports Third Quarter 2009 Financial and Operating Results	11th November, 2009	AETERNA ZENTARIS INC.	All amounts are in U.S. dollars QUEBEC CITY, Nov. 11 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on
AEterna Zentaris: Scientific Article Supports Perifosine's Development in Kidney Cancer	9th November, 2009	AETERNA ZENTARIS INC.	Article published in December 2009 issue of the Journal of Urology QUEBEC CITY, Nov. 9 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a global
AEterna Zentaris to Announce Third Quarter 2009 Financial and Operating Results on November 11, 2009	4th November, 2009	AETERNA ZENTARIS INC.	QUEBEC CITY, Nov. 4 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology,
AEterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer	2nd November, 2009	AETERNA ZENTARIS INC.	Preliminary evaluation after completion of treatment phase shows that primary efficacy endpoint has been met for patients with advanced-stage platinum-resistant, taxane-pretreated ovarian

BioNews Results for AEterna Zentaris:
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology	SmartBrief:  Nov 15 2009 4:45AM Matching: aeterna zentaris
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activi	Entrepreneur.com:  Nov 12 2009 3:49PM Matching: aeterna zentaris
Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine)	Genetic Engineering News:  Nov 12 2009 12:30PM Matching: aeterna zentaris
AEterna Zentaris (AEZS) Partner, Keryx Biopharmaceuticals (KERX), Announces Poster Presentation Highlighting C	BioSpace:  Nov 11 2009 3:43PM Matching: aeterna zentaris
AEterna Zentaris Partner, Keryx Biopharmaceuticals, Announces Poster Presentation Highlighting Clinical Activity of Perifosine (KRX-0401) at 51st Annual Meeting of the American Society of Hematology	Street Insider:  Nov 11 2009 1:53PM Matching: aeterna zentaris
Promote your company here: BioNewsCast - Press Release Distribution	→View more AEterna Zentaris news.

AEterna Zentaris Clinical Trials:
Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)

AEterna Zentaris Patents:
US Patent No.	Title
7605121	Oligopeptide lyophilisate, their preparation and use
7393834	LHRH-antagonists in the treatment of fertility disorders
7365081	Indole derivatives and their use as medicaments
7323468	Pyridopyrazines and the use thereof as kinase inhibitors
7288517	Treatment of dementia and neurodegenerative diseases with intermediate doses of LHRH antagonists
→View more AEterna Zentaris patents.

AEterna Zentaris (AEZS) Financial information Links from Barchart
AEZS Quote from from Barchart.com
AEZS Chart from from Barchart.com
AEZS Profile from from Barchart.com
AEZS Opinion from from Barchart.com
→View more AEterna Zentaris finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 576 times since April 2007, the link to the organisation's website has been followed 104 times

Search for more companies in Québec

Search for more companies in

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for AEterna Zentaris